
Early trial shows strong pancreatic cancer response for vopimetostat combo, but more data needed.
Tango Therapeutics' drug vopimetostat combined with daraxonrasib has shown a promising early signal in treating pancreatic cancer, based on a small group of 12 previously treated patients. A larger Phase 3 trial is planned to test the drug as a first...


